Roubaix Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Roubaix Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,112	Closed	-$2.27M	–	52
2025 Q3	$2.27M	Buy	+8,112	New	+$2.21M	1.06%	44
2025 Q1	–	Sell	-11,303	Closed	-$3.71M	–	55
2024 Q4	$3.71M	Buy	+11,303	New	+$3.84M	1.78%	31
2024 Q3	–	Sell	-8,996	Closed	-$2.46M	–	51
2024 Q2	$2.46M	Sell	8,996 -6,747	-43%	-$1.96M	1.55%	34
2024 Q1	$5.45M	Buy	15,743 +3,194	+25%	+$1.05M	3.44%	8
2023 Q4	$4.05M	Buy	+12,549	New	+$3.93M	2.84%	13
2019 Q4	–	Sell	-7,496	Closed	-$2.49M	–	38
2019 Q3	$2.49M	Sell	7,496 -11,789	-61%	-$3.85M	2.27%	22
2019 Q2	$6.03M	Buy	+19,285	New	+$5.77M	5.03%	3

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Roubaix Capital's BIO Position: Q4 2025 in Review

Roubaix Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2025, closing a stake of 8,112 shares — an estimated $2.27M sold.

Roubaix Capital first reported a position in BIO in Q2 2019 and held it in 7 quarters. The position peaked at $6.03M in Q2 2019. 398 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

Roubaix Capital reported no remaining Bio-Rad Laboratories Class A position as of Q4 2025 after selling out during the quarter.
Roubaix Capital sold 8,112 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $2.27M.
Roubaix Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 7 quarters.
Roubaix Capital's Bio-Rad Laboratories Class A position peaked at $6.03M in Q2 2019.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Roubaix Capital's 13F filing for Q4 2025, filed 9 Feb 2026.